Naxitamab key points.PNG (84.93 kB)
Naxitamab: First Approval
online resource
posted on 2021-02-16, 22:25 authored by Anthony MarkhamDeclarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here
Abstract
Naxitamab
(DANYELZA®, naxitamab-gqgk) is a humanised (IgG1) anti-GD2 (hu3F8)
monoclonal antibody was developed by the Memorial Sloan Kettering Cancer Center
(with commercial rights licenced to Y-mAbs therapeutics Inc.) for the treatment
of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was recently granted accelerated
approval by the US FDA for marketing as treatment (in combination with granulocyte-macrophage colony-stimulating factor)
for paediatric patients at least one year of age and adult patients with
relapsed or refractory high-risk neuroblastoma in the bone or bone marrow
demonstrating a partial response, minor response, or stable disease to prior
therapy.
This article summarizes the milestones in the development of naxitamab leading
to this first approval.
© Springer Nature Switzerland AG 2021